[L.-R.] Luis Voloch, PhD., Chief Technology Officer of Immunai, and Noam Solomon, PhD, the company’s CEO and Co-founder. Immunai has completed a $60 million Series A financing that it says will enable its expansion into functional genomics, with the goal of improving how it integrates artificial intelligence (AI) and single-cell multi-omics at scale to help its biopharma and healthcare partners better detect, diagnose, and treat disease. [Immunai]
Immunai said the new funding will allow it to expand its genomics capabilities from the observational to the functional, including reprogramming immune cells as well as prioritizing and validating targets . . .